HRA Proposes OTC Norgestrel Birth Control

HRA has worked with Ibis Reproductive Health, which supports the Free the Pill advocacy group, to conduct research for a norgestrel switch NDA.

• Source: Shutterstock

HRA Pharma submitted the first new drug application in the US for an OTC oral contraceptive, proposing a re-launch of Opill (0.075 mg norgestrel) it previously marketed Rx with more than 50 years of successful and safe use preventing pregnancies.

The FDA approved Rx sales of Opill in 1973 as a progesterone-only daily birth control pill. HRA, a French pharma...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Rx-to-OTC Switch

More from Health